Advisory Committee to Review Boehringer Ingelheim's HIV Candidate Aptivus
The FDA's Antiviral Drugs Advisory Committee will convene May 19 to discuss Boehringer Ingelheim's new drug application for Aptivus.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.